此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The Effectiveness and Safety of Hypertonic Citrate Adenine-New (HCA-N) Solution for the Preservation of Kidney Grafts During Kidney Transplantation

2026年9月17日 更新者:Zhongnan Hospital

A Multicenter, Randomized, Double-blind, Positive-control, Non-inferiority Clinical Trial on the Effectiveness and Safety of Hypertonic Citrate Adenine-New (HCA-N) Solution for the Preservation of Kidney Grafts During Kidney Transplantation

To verify the effectiveness and safety of the HCA-N solution in actual clinical preservation, this study intends to conduct a prospective, randomized, and positive control clinical trial. Using the classic HTK solution as a reference, the study will focus on evaluating the performance of the HCA-N solution in terms of the incidence of delayed recovery of transplant kidney function and the speed of early renal function recovery, with the aim of providing better preservation solution selection and high-level evidence-based guidance for clinical practice in kidney transplantation.

研究概览

地位

主动,不招人

条件

详细说明

This is a multicenter, randomized, double-blind, positive-controlled, non-inferiority clinical trial evaluating HCA-N Solution versus Histidine-Tryptophan-Ketoglutarate (HTK) Solution for the preservation of donor kidneys in renal transplantation. HCA-N Solution is a Class III device intended for flushing and preserving isolated kidneys for clinical renal transplantation. Approximately 250 subjects will be enrolled, with 125 subjects in the test group and 125 in the control group, across approximately 20 centers. Donor-recipient pairs must meet the protocol-defined eligibility criteria; eligibility details are provided in the Eligibility Criteria section, and randomization will be 1:1 to the test or control group.

During the screening period (Visit 1 [V1], Day -14 to Day -1 [D-14 to D-1]), potential donors and recipients will be screened for eligibility, informed consent will be obtained, and baseline demographic, medical, immunological, and laboratory information will be collected. The recipient's preoperative baseline estimated glomerular filtration rate (eGFR) value, defined as the last value before transplantation, will be recorded.

On surgery day (Visit 2 [V2], Day 0 [D0]), enrollment and randomization will occur. Vital signs will be recorded, renal transplantation surgery will be performed, and the donor kidney will be flushed and preserved using the assigned preservation solution. Device deficiencies, post-transplant dialysis events, adverse events (AEs), and concomitant treatments will be recorded.

Follow-up visits will occur at Visit 3 (V3, Day 1 [D1]), Visit 4 (V4, Day 3 [D3]), Visit 5 (V5, Day 7 [D7] ± 1), Visit 6 (V6, Day 14 [D14] ± 2), and Visit 7 (V7, Day 28 [D28] ± 3). At these visits, vital signs, laboratory tests including complete blood count, blood biochemistry, and urinalysis, eGFR, dialysis events, adverse events, and concomitant treatments will be recorded. The Day 28 visit will also include physical examination, coagulation function, pregnancy testing for women of childbearing potential, 12-lead electrocardiogram (ECG), and chest computed tomography (CT) or X-ray. Long-term follow-up will collect eGFR, graft survival status, patient survival information, and device-related adverse events.

Efficacy will be assessed primarily by the occurrence of delayed graft function (DGF) after transplantation, with additional renal function parameters within 28 days post-transplantation as specified in the Outcome Measures section. Safety will be evaluated through AEs, serious adverse events (SAEs), vital signs, physical examination, laboratory parameters, ECG, and other protocol-specified assessments.

Statistical analysis will be performed according to prespecified analysis sets. For the primary endpoint, between-group comparisons will use chi-square test, corrected chi-square test, or Fisher's exact test as appropriate, with 95% confidence intervals calculated. Binary secondary endpoints will be analyzed using similar categorical methods. Time-to-event endpoints will be analyzed using the Kaplan-Meier method, including median time, 25%/75% percentiles, 95% confidence intervals, and Kaplan-Meier curves. Continuous eGFR changes from baseline at Days 1, 3, 7, 14, and 28 post-transplantation will be summarized descriptively by group and compared using t-test or rank-sum test as appropriate. Safety analyses will be based on the Safety Set (SS) and will summarize AEs and SAEs by number of events, number of subjects, and incidence rates; AEs will be summarized by severity, System Organ Class (SOC)/Preferred Term (PT), and relationship to the study product. Physical examination, vital signs, 12-lead ECG, and laboratory results will be summarized descriptively.

研究类型

介入性

注册 (估计的)

250

阶段

  • 阶段2
  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Hubei
      • Wuhan、Hubei、中国、430071
        • Zhongnan Hospital of Wuhan University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Recipients must meet all of the following criteria:

  • Age 18 to 65 years (inclusive), regardless of gender.
  • Diagnosed as eligible for allogeneic renal transplantation and willing to undergo allogeneic renal transplantation.
  • Understand and agree to comply with the study requirements and voluntarily sign the informed consent form.
  • Require renal transplantation and be first-time transplant recipients.

Donors must meet all of the following criteria:

  • Donor kidney source aged 18 to 65 years (inclusive), regardless of gender.
  • Donor's last serum creatinine before kidney procurement < 2 mg/dL (177 μmol/L), and not having received hemodialysis.

Exclusion Criteria:

Recipients meeting any of the following criteria will be excluded:

  • Planned for dual kidney transplantation.
  • Planned for multi-organ combined transplantation.
  • History of previous organ transplantation.
  • Concurrent severe diseases, such as severe hepatic impairment, cardiopulmonary insufficiency, coagulation disorders, etc.
  • Diagnosis of malignant tumor within 5 years prior to enrollment (except for adequately treated cervical carcinoma in situ, localized cutaneous squamous cell carcinoma, basal cell carcinoma, prostate cancer not requiring antitumor therapy, thyroid cancer, breast ductal carcinoma in situ, and urothelial carcinoma below T1 stage).
  • Panel reactive antibody (PRA) > 10%.
  • Pregnant or lactating women.
  • Participation in other drug or device clinical trials within 3 months prior to enrollment.
  • Donors meeting any of the following criteria will be excluded:
  • Donor has received renal replacement therapy (hemodialysis or continuous renal replacement therapy [CRRT]) prior to screening.
  • Donor has infectious diseases unsuitable for transplantation.

Other requirements:

  • ABO blood group system incompatibility between donor and recipient.
  • Donor kidney warm ischemia time > 10 minutes, or cold ischemia time > 24 hours.
  • Mechanical perfusion preservation required as assessed by the investigator.
  • Other conditions that the investigator deems inappropriate for participation in this trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Evaluate the Efficacy and Safety of HCA-N Solution for Preservation of Donor Kidneys

To evaluate the safety and efficacy of HCA-N Solution for the preservation of donor kidneys in renal transplantation, through a comparative study with HTK Solution in kidney organ transplantation.

Experimental Group using HCA-N Solution for the preservation of donor kidneys in renal transplantation

假比较器:comparative with HTK Solution in kidney organ transplantation.

The commonly used methods in clinical practice

control group using HTK Solution in kidney organ transplantation

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of subjects experiencing delayed graft function (DGF) post-transplantation.
大体时间:Baseline at Days 1, 3, 7, 14, and 28 post-transplantation

DGF is defined as the need for dialysis within 1 week after transplantation.

Baseline at Days 1, 3, 7, 14, and 28 post-transplantation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月5日

初级完成 (估计的)

2028年4月9日

研究完成 (估计的)

2028年4月9日

研究注册日期

首次提交

2026年9月13日

首先提交符合 QC 标准的

2026年9月13日

首次发布 (实际的)

2026年9月17日

研究记录更新

最后更新发布 (实际的)

2026年9月22日

上次提交的符合 QC 标准的更新

2026年9月17日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

The clinical project is underway and the data must be kept confidential.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅